OTCMKTS:OXBDF Oxford Biomedica (OXBDF) Stock Price, News & Analysis $4.66 0.00 (0.00%) As of 06/13/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesShort InterestBuy This Stock About Oxford Biomedica Stock (OTCMKTS:OXBDF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Oxford Biomedica alerts:Sign Up Key Stats Today's Range$4.66▼$4.6650-Day Range$3.15▼$4.6652-Week Range$3.15▼$5.68VolumeN/AAverage Volume12,757 shsMarket Capitalization$493.78 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewOxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its s LentiVector platform technology is an advanced lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The Platform segment engages in bioprocessing and process development activities for third parties. The Product segment is involved in the research and development of new gene therapeutic product candidates. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, and adenoviral vectors. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.Read More… Receive OXBDF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oxford Biomedica and its competitors with MarketBeat's FREE daily newsletter. Email Address OXBDF Stock News HeadlinesOxford BioMedica touts strong first-half momentum ahead of meetingJune 11, 2025 | lse.co.ukOxford Biomedica Full Year 2024 Earnings: EPS Beats ExpectationsMay 1, 2025 | finance.yahoo.comSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bill Gates has backed four companies in this space. The World Economic Forum calls it “the most exciting human discovery since fire.” Whitney Tilson believes this trend could mint a new class of wealthy investors—and he’s sharing one stock to watch now, for free.June 16, 2025 | Stansberry Research (Ad)Oxford BioMedica (OXBDF) Receives a Buy from RBC CapitalApril 15, 2025 | theglobeandmail.comWhen Will Oxford Biomedica plc (LON:OXB) Turn A Profit?April 10, 2025 | uk.finance.yahoo.comOxford Biomedica sees FY25 revenue GBP 160M-GBP 170MApril 9, 2025 | msn.comOxford Biomedica prepares statements on ‘going concern basis’April 9, 2025 | msn.comOxford Biomedica plc (OXBDF) Q4 2024 Earnings Call TranscriptApril 9, 2025 | seekingalpha.comSee More Headlines OXBDF Stock Analysis - Frequently Asked Questions How have OXBDF shares performed this year? Oxford Biomedica's stock was trading at $5.3950 at the beginning of 2025. Since then, OXBDF shares have decreased by 13.6% and is now trading at $4.66. View the best growth stocks for 2025 here. How do I buy shares of Oxford Biomedica? Shares of OXBDF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today6/15/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Private households Sub-IndustryN/A Current SymbolOTCMKTS:OXBDF Previous SymbolNASDAQ:OXBDF CIKN/A Webwww.oxfordbiomedica.co.uk Phone44-18-6578-3000FaxN/AEmployees891Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio1.48 Current Ratio2.35 Quick Ratio2.07 Sales & Book Value Annual Sales$111.34 million Price / Sales4.43 Cash FlowN/A Price / Cash FlowN/A Book Value$1.01 per share Price / Book4.61Miscellaneous Outstanding Shares105,962,000Free FloatN/AMarket Cap$493.78 million OptionableNot Optionable Beta1.09 20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free Report This page (OTCMKTS:OXBDF) was last updated on 6/16/2025 by MarketBeat.com Staff From Our PartnersAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | Sponsored[First Look] Get in before potential 10X AI announcementsGo for 10X gains from the next big AI announcement — starting as soon as 7 days from now Former floor trade...Masters in Trading | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredGet in stocks now - and get out on this dateGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oxford Biomedica plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Oxford Biomedica With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.